PLK1 targets NOTCH1 during DNA damage and mitotic progression.
Apoptosis
/ drug effects
Arsenites
/ toxicity
Cell Cycle Checkpoints
/ drug effects
Cell Cycle Proteins
/ antagonists & inhibitors
Cell Line
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cytokines
/ metabolism
DNA Damage
Down-Regulation
/ drug effects
G2 Phase
/ drug effects
Humans
Inflammation Mediators
/ metabolism
Keratinocytes
/ drug effects
Mitosis
/ drug effects
Phosphorylation
/ drug effects
Protein Serine-Threonine Kinases
/ antagonists & inhibitors
Proteolysis
/ drug effects
Proto-Oncogene Proteins
/ antagonists & inhibitors
Receptor, Notch1
/ metabolism
Substrate Specificity
/ drug effects
Polo-Like Kinase 1
Arsenic
DNA damage
DNA damage response
Notch
Notch pathway
PLK1
cancer biology
cell cycle
cell transformation
stress response
Journal
The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R
Informations de publication
Date de publication:
22 11 2019
22 11 2019
Historique:
received:
21
06
2019
revised:
25
09
2019
pubmed:
11
10
2019
medline:
11
6
2020
entrez:
11
10
2019
Statut:
ppublish
Résumé
Notch signaling plays a complex role in carcinogenesis, and its signaling pathway has both tumor suppressor and oncogenic components. To identify regulators that might control this dual activity of NOTCH1, we screened a chemical library targeting kinases and identified Polo-like kinase 1 (PLK1) as one of the kinases involved in arsenite-induced NOTCH1 down-modulation. As PLK1 activity drives mitotic entry but also is inhibited after DNA damage, we investigated the PLK1-NOTCH1 interplay in the G
Identifiants
pubmed: 31597699
pii: S0021-9258(20)30368-9
doi: 10.1074/jbc.RA119.009881
pmc: PMC6879332
doi:
Substances chimiques
Arsenites
0
Cell Cycle Proteins
0
Cytokines
0
Inflammation Mediators
0
Proto-Oncogene Proteins
0
Receptor, Notch1
0
Protein Serine-Threonine Kinases
EC 2.7.11.1
arsenite
N5509X556J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17941-17950Informations de copyright
© 2019 De Blasio et al.
Références
Leukemia. 2013 Feb;27(2):485-8
pubmed: 22846929
Nat Rev Cancer. 2017 Mar;17(3):145-159
pubmed: 28154375
Science. 2011 Aug 26;333(6046):1154-7
pubmed: 21798897
Curr Mol Med. 2014 Jan;14(1):34-44
pubmed: 24236458
Oncogene. 2008 Sep 1;27(38):5115-23
pubmed: 18758480
Nature. 1999 Apr 8;398(6727):518-22
pubmed: 10206645
Front Immunol. 2018 Aug 14;9:1823
pubmed: 30154786
Int J Mol Sci. 2019 Mar 01;20(5):null
pubmed: 30832234
Mol Cell. 2004 Sep 10;15(5):799-811
pubmed: 15350223
Nat Genet. 2003 Mar;33(3):416-21
pubmed: 12590261
Cell Cycle. 2014;13(13):2046-55
pubmed: 24801890
Cell. 2009 Apr 17;137(2):216-33
pubmed: 19379690
EMBO J. 2004 May 19;23(10):2116-25
pubmed: 15103331
Mol Cell. 2010 Nov 24;40(4):606-18
pubmed: 21095590
J Biol Chem. 2002 Nov 15;277(46):44115-20
pubmed: 12207013
Oncogene. 2015 Sep 10;34(37):4799-807
pubmed: 25619835
Cancer Cell. 2014 Oct 13;26(4):455-64
pubmed: 25314076
EMBO J. 2001 Jul 2;20(13):3427-36
pubmed: 11432830
Mol Cancer Ther. 2016 Jul;15(7):1427-35
pubmed: 27330107
Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17761-6
pubmed: 22006338
Leukemia. 2015 Dec;29(12):2442-5
pubmed: 25982911
J Cell Sci. 2014 Feb 15;127(Pt 4):801-11
pubmed: 24338364
Elife. 2017 Dec 19;6:
pubmed: 29254517
Science. 1999 Apr 30;284(5415):770-6
pubmed: 10221902
Oncogene. 2005 Apr 18;24(17):2844-59
pubmed: 15838519
Development. 1999 Sep;126(17):3925-35
pubmed: 10433920
Nat Cell Biol. 2009 Aug;11(8):973-9
pubmed: 19597488
Dev Biol. 2000 Dec 15;228(2):151-65
pubmed: 11112321
Science. 2001 Oct 5;294(5540):173-7
pubmed: 11533444
Biochim Biophys Acta. 2016 Feb;1863(2):303-13
pubmed: 26592459
Cancer Res. 2014 Feb 15;74(4):1091-104
pubmed: 24351288